Due to oxidative instability, arylboronic acids are not compatible with the solid-phase synthesis of nucleic acids. We solved this problem and, based on these findings, developed siRNA prodrugs activated in the presence of reactive oxygen species (ROS) in vivo. These prodrugs can be used for specific targeting of ROS-rich cancer cells.
J. Rühle, I. Klemt, T. Abakumova, O. Sergeeva, P. Vetosheva, T. Zatsepin and A. Mokhir, Chem. Commun., 2022, 58, 4388 DOI: 10.1039/D2CC00651K
To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.
If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.
If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.
Read more about how to correctly acknowledge RSC content.
Please wait while we load your content...
